An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Mosakhani, Neda ^a   Guled, Mohamed ^a   Leen, Gayle ^b   Calabuig Farĩas, Silvia ^c   Niini, Tarja ^a   MacHado, Isidro ^c   Savola, Suvi ^a   Scotlandi, Katia ^d   López Guerrero, José Antonio ^e   Llombart Bosch, Antonio ^c   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c UNIVERSITY OF VALENCIA   (Spain)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Copy number; Ewing's sarcoma xenograft; Microarray; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 106; MICRORNA 145; MICRORNA 31; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CHROMOSOME 15; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 8; CHROMOSOME 9P; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EWING SARCOMA; EWSR1 GENE; FLI1 GENE; GENE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; TUMOR XENOGRAFT; ANIMAL; CLUSTER ANALYSIS; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; REPRODUCIBILITY; XENOGRAFT;

ANIMALS; CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; REPRODUCIBILITY OF RESULTS; SARCOMA, EWING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84858409309     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-24     Document Type: Article

References (53)

1. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S, BMC Cancer 2009 9 17 10.1186/1471-2407-9-17 19144156
2. Lung cancer xenografting alters microRNA profile but not immunophenotype. Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, Hylander B, Yendamuri S, Ramnath N, Biochem Biophys Res Commun 2009 386 305 310 10.1016/j.bbrc.2009. 06.021 19523437
3. A Tissue Microarray Study of Osteosarcoma: Histopathologic and Immunohistochemical Validation of Xenotransplanted Tumors as Preclinical Models. Mayordomo E, Machado I, Giner F, Kresse SH, Myklebost O, Carda C, Navarro S, Llombart-Bosch A, Appl Immunohistochem Mol Morphol 2010 18 453 461 20436344
4. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson HF Jr, Knuutila S, Powell SM, Cancer Res 1998 58 34 37 9426053 (Pubitemid 28027712)
5. Molecular characterization of the pediatric preclinical testing panel. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ, Clin Cancer Res 2008 14 4572 4583 10.1158/1078-0432.CCR-07- 5090 18628472
6. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J, Cancer Res 2007 67 32 40 10.1158/0008-5472.CAN-06-0610 17210681 (Pubitemid 46142757)
7. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Cancer Res 1995 55 4670 4675 7553647
8. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J, Clin Cancer Res 2008 14 6456 6468 10.1158/1078-0432.CCR-08-0138 18927285
9. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH, Clin Cancer Res 2000 6 4932 4938 11156254 (Pubitemid 32110439)
10. MicroRNAs: novel biomarkers for human cancer. Bartels CL, Tsongalis GJ, Clin Chem 2009 55 623 631 10.1373/clinchem.2008.112805 19246618
11. Many roads to maturity: microRNA biogenesis pathways and their regulation. Winter J, Jung S, Keller S, Gregory RI, Diederichs S, Nat Cell Biol 2009 11 228 234 10.1038/ncb0309-228 19255566
12. An analysis of human microRNA and disease associations. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q, PLoS One 2008 3 3420 10.1371/journal.pone. 0003420 18923704
13. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I, Cancer Res 2005 65 11459 11468 10.1158/0008-5472.CAN-05-1696 16357154 (Pubitemid 41821703)
14. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr, Cancer Res 2005 65 8698 8705 10.1158/0008-5472.CAN-05-1704 16204038 (Pubitemid 41377357)
15. Mesenchymal stem cell features of Ewing tumors. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O, Cancer Cell 2007 11 421 429 10.1016/j.ccr.2007.02.027 17482132 (Pubitemid 46680428)
16. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors. Potikyan G, France KA, Carlson MR, Dong J, Nelson SF, Denny CT, Lab Invest 2008 88 1291 1302 10.1038/labinvest.2008.99 18838963
17. Ewing's sarcoma origin: from duel to duality. Riggi N, Suva ML, Stamenkovic I, Expert Rev Anticancer Ther 2009 9 1025 1030 10.1586/era.09.81 19671021
18. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, Hotfilder M, Lowel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Muller-Tidow C, Burdach S, Proc Natl Acad Sci USA 2009 106 5324 5329 10.1073/pnas.0810759106 19289832
19. Modeling initiation of Ewing sarcoma in human neural crest cells. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, Hsu JH, Lawlor ER, PLoS One 2011 6 19305 10.1371/journal.pone.0019305 21559395
20. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K, J Pathol 2012 226 796 805 10.1002/path.3007 21960059
21. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J, Kovar H, Oncogene 2011 30 2173 2180 10.1038/onc.2010.581 21217773
22. MicroRNAs. Fabbri M, Croce CM, Calin GA, Cancer J 2008 14 1 6 10.1097/PPO.0b013e318164145e 18303474
23. Prognostic impact of P53 status in Ewing sarcoma. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M, Cancer 2000 89 783 792 10.1002/1097-0142(20000815)89:4<783::AID- CNCR10>3.0.CO;2-Q 10951341 (Pubitemid 30658577)
24. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M, J Clin Oncol 2005 23 548 558 15659501 (Pubitemid 46224232)
25. P53 mutations in Ewing's sarcoma. Park YK, Chi SG, Kim YW, Park HR, Unni KK, Oncol Rep 2001 8 533 537 11295075
26. Does the GH-IGF axis play a role in cancer pathogenesis? Cohen P, Clemmons DR, Rosenfeld RG, Growth Horm IGF Res 2000 10 297 305 10.1054/ghir.2000.0171 11161960 (Pubitemid 32125100)
27. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL, Cancer Res 1995 55 129 134 7805022
28. IGF-I receptor signalling in transformation and differentiation. Valentinis B, Baserga R, Mol Pathol 2001 54 133 137 10.1136/mp.54.3.133 11376123 (Pubitemid 32539602)
29. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, Baserga R, J Cell Physiol 2009 220 485 491 10.1002/jcp.21796 19391107
30. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Cohen P, Lamson G, Okajima T, Rosenfeld RG, Mol Endocrinol 1993 7 380 386 10.1210/me.7.3.380 7683373 (Pubitemid 23104526)
31. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. Rajah R, Valentinis B, Cohen P, J Biol Chem 1997 272 12181 12188 10.1074/jbc.272.18.12181 9115291 (Pubitemid 27202802)
32. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. Schedlich LJ, Young TF, Firth SM, Baxter RC, J Biol Chem 1998 273 18347 18352 10.1074/jbc.273.29.18347 9660801 (Pubitemid 28334760)
33. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. Singh B, Charkowicz D, Mascarenhas D, J Biol Chem 2004 279 477 487 14576163 (Pubitemid 38044849)
34. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Prieur A, Tirode F, Cohen P, Delattre O, Mol Cell Biol 2004 24 7275 7283 10.1128/MCB.24.16.7275-7283.2004 15282325 (Pubitemid 39014452)
35. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suva D, Tercier S, Joseph JM, Guillou L, Stamenkovic I, Genes Dev 2010 24 916 932 10.1101/gad.1899710 20382729
36. Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genove G, Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ, Kreuger J, Lindahl P, Genome Med 2009 1 108 10.1186/gm108 19917099
37. Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G, Wiemann S, Sahin O, J Pathol 2010 220 71 86 10.1002/path.2610 19768731
38. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA, Cancer Cell 2006 9 435 443 10.1016/j.ccr.2006.04.020 16766263 (Pubitemid 43832188)
39. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T, Asko-Seljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA, Tukiainen E, Caballin MR, Myklebost O, Knuutila S, Br J Cancer 1997 75 1403 1409 10.1038/bjc.1997.242 9166930 (Pubitemid 27196858)
40. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Bohling T, Ekfors T, Virolainen M, Lindholm P, Monge O, Picci P, Knuutila S, Elomaa I, Cancer Genet Cytogenet 1999 114 35 41 10.1016/S0165-4608(99)00031-X 10526533 (Pubitemid 29469689)
41. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, Aurias A, Cancer Genet Cytogenet 2001 130 57 61 10.1016/S0165-4608(01)00454-X 11672775 (Pubitemid 32979167)
42. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, Hoffmann C, Hillmann A, Wai D, Schaefer KL, Boecker W, Juergens H, Winkelmann W, Dockhorn-Dworniczak B, Genes Chromosomes Cancer 2001 32 164 171 10.1002/gcc.1178 11550284 (Pubitemid 32847161)
43. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Farinas S, Picci P, Llombart-Bosch A, Int J Cancer 2011 128 1139 1150 10.1002/ijc.25424 20473914
44. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A, Lab Invest 2001 81 803 814 11406642 (Pubitemid 32553402)
45. Molecular cytogenetic parameters in Ewing sarcoma. Amiel A, Ohali A, Fejgin M, Sardos-Albertini F, Bouaron N, Cohen IJ, Yaniv I, Zaizov R, Avigad S, Cancer Genet Cytogenet 2003 140 107 112 10.1016/S0165-4608(02)00659-3 12645647 (Pubitemid 36349009)
46. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Ferreira BI, Alonso J, Carrillo J, Acquadro F, Largo C, Suela J, Teixeira MR, Cerveira N, Molares A, Gomez-Lopez G, Pestana A, Sastre A, Garcia-Miguel P, Cigudosa JC, Oncogene 2008 27 2084 2090 10.1038/sj.onc.1210845 17952124 (Pubitemid 351442743)
47. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Potschger U, Gadner H, Ambros PF, Genes Chromosomes Cancer 1999 24 243 254 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A 10451705 (Pubitemid 29070164)
48. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M, J Clin Oncol 2005 23 548 558 15659501 (Pubitemid 46224232)
49. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM, Proc Natl Acad Sci USA 2004 101 2999 3004 10.1073/pnas.0307323101 14973191 (Pubitemid 38327724)
50. microRNAs exhibit high frequency genomic alterations in human cancer. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G, Proc Natl Acad Sci USA 2006 103 9136 9141 10.1073/pnas.0508889103 16754881 (Pubitemid 43902545)
51. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY, RNA 2008 14 2348 2360 10.1261/rna.1034808 18812439
52. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA, Cell 2009 137 1032 1046 10.1016/j.cell.2009.03.047 19524507
53. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M, Schaefer KL, de Alava E, Oncogene 2011 31 1287 1298 21822310